With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.33527-91-2,Tris[2-(dimethylamino)ethyl]amine,as a common compound, the synthetic route is as follows.
Embodiment 5Production of [Cu(Me6tren)]BPh4 0.20 g (0.87 mmol) Me6tren (1) was dissolved in approx. 2 ml acetone and a solution of 0.30 g (0.81 mmol) [Cu(CH3CN)4]PF6 (tetrakis(acetonitrile)copper(I)-hexafluorophosphate) in approx. 4 ml acetone was added slowly under constant stirring. A solution of 0.28 g (0.82 mmol) NaBPh4 (sodium tetraphenylborate) in approx. 2 mL acetone was added subsequently to the colorless, complex solution thus obtained, for the replacement of anions. For the preparation of the solid, the complex solution was added to 20 ml diethylether. The voluminous solid of [Cu(Me6tren)]BPh4 (10) obtained was dried in vacuum. 0.48 g (96.6%) of a colorless powder was obtained as the product.All work was carried out in an argon box. It is possible, however, to carry out all work with the Schlenk technique under argon or nitrogen as well.The complex [Cu(Me6tren)]BPh4 is shown in FIG. 1.The results of the crystal structure analysis of [Cu(Me6tren)]BPh4 are shown in FIG. 2.
The synthetic route of 33527-91-2 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; Schindler, Siegfried; Wuertele, Christian; US2012/16127; (2012); A1;,
Chiral nitrogen ligands in late transition metal-catalysed asymmetric synthesis¡ªI. Addressing the problem of ligand lability in rhodium-catalysed hydrosilations
Nitrogen-Containing Ligands for Asymmetric Homogeneous and Heterogeneous Catalysis